[Articles] Pneumococcal conjugate vaccine 13 delivered as one primary and one booster dose (1  + 1) compared with two primary doses and a booster (2 + 1) in UK infants: a multicentre, parallel group randomised controlled trial

Our findings show that for nine of the 13 serotypes in PCV13, post-booster responses in infants primed with a single dose are equivalent or superior to those seen following the standard UK 2 + 1 schedule. Introducing a 1 + 1 schedule in countries with a mature PCV programme and established herd immunity is likely to maintain population control of vaccine-type pneumococcal disease.

Source: The Lancet Infectious Diseases - November 22, 2017 Category: Infectious Diseases Authors: David Goldblatt, Jo Southern, Nick J Andrews, Polly Burbidge, Jo Partington, Lucy Roalfe, Marta Valente Pinto, Vasilli Thalasselis, Emma Plested, Hayley Richardson, Matthew D Snape, Elizabeth Miller Tags: Articles Source Type: research